A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Pfizer
Rutgers, The State University of New Jersey
Pfizer
Roswell Park Cancer Institute
MedImmune LLC
Pfizer
Inspirna, Inc.
Gruppo Oncologico del Nord-Ovest
Roswell Park Cancer Institute
Alliance for Clinical Trials in Oncology
Pfizer
Bayer
City of Hope Medical Center
Vall d'Hebron Institute of Oncology
NuCana plc
Pfizer
Leap Therapeutics, Inc.
City of Hope Medical Center
Georgetown University
UNC Lineberger Comprehensive Cancer Center
Sapience Therapeutics
NuCana plc
Al-Mustansiriyah University
Affiliated Hospital of Nantong University
Alliance for Clinical Trials in Oncology
Ohio State University Comprehensive Cancer Center
Al-Azhar University
NSABP Foundation Inc
Asan Medical Center
Dutch Colorectal Cancer Group
Eastern Cooperative Oncology Group
Genentech, Inc.
Amgen
Institut Bergonié
SCRI Development Innovations, LLC
NSABP Foundation Inc
University of Louisville
Hospital Universitari de Bellvitge
Fox Chase Cancer Center
UNICANCER
Federation Francophone de Cancerologie Digestive
Federation Francophone de Cancerologie Digestive
Peking University People's Hospital
Alliance for Clinical Trials in Oncology
Abramson Cancer Center at Penn Medicine
Federation Francophone de Cancerologie Digestive
Federation Francophone de Cancerologie Digestive